Opdualag 240 mg / 80 mg sterile concentrate

Licence status
Authorised: 15/06/2022
Active substances
RELATLIMAB, Nivolumab
Dosage Form
Concentrate for solution for infusion
Licence number
EU/1/22/1679/001
Licence holder
Bristol-Myers Squibb Pharma EEIG

Product documents

Licence information

ATC code
L01XY Combinations of antineoplastic agents, L01XY03 Relatlimab Nivolumab
Legal supply status
Product subject to prescription which may not be renewed (A)
Place of sale
Supply through pharmacies only
Conditions of Licence
Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Marketing availability
Unknown
Advertising conditions
Advertising to healthcare professionals only
Licence issued
15/06/2022

Educational materials for patients